<?xml version="1.0" encoding="UTF-8"?>
<p id="p0150">The nucleoside analogue Ribavirin has extensive activity against DNA and RNA viruses and it is used to treat SARS-CoV patients [
 <xref rid="bb0570" ref-type="bibr">114</xref>,
 <xref rid="bb0575" ref-type="bibr">115</xref>]. The exact antiviral mechanism of Ribavirin has been studied for decades and it is still unclear. Ribavirin usage is associated the major side effect of anaemia which is found in 27â€“59% of patients. The importance of Ribavirin for fighting against SARS-CoV-2 was evaluated in combination with protease inhibitors and corticosteroids [
 <xref rid="bb0580" ref-type="bibr">116</xref>]. This drug has been showing significant results with Sofosbuvir and this combination is under the clinical trials (
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT01497366" id="ir0260" xmlns:xlink="http://www.w3.org/1999/xlink">NCT01497366</ext-link>).
</p>
